therapeutic antibodies News
-
Immune Biosolutions will continue its growth at EspaceLabz
Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in the new EspaceLabz center, located in the Sherbrooke’s Scientific Park. In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions’ ...
-
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...
-
Immune Biosolutions selected for JLABS @ Toronto
Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto. Initiated and managed by the pharmaceutical company Johnson & Johnson, JLABS are a network of 6 tech incubators focusing on life sciences. The newest facility, JLABS @ Toronto, located in the MaRS district, is the first located outside the US. JLABS ...
-
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and ...
-
New Research Collaboration with Janssen Biotech
Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology. The ...
-
Universal flu vaccine pioneer EnGen Bio announces a registered equity crowdfunding campaign, in partnership with WeFunder.
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global Influenza Strategy (2019–2030) ...
-
Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants
Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In ...
-
IntoCell and Ab Studio to Start Research Collaboration
IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, today announced the signing of a research collaboration with Ab Studio, a US biotech focused on the discovery of novel antibodies. The collaboration will include construction of a panel of ADCs by integrating IntoCell's proprietary payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) ...
-
Confo Therapeutics Enters Collaborative Agreement With Regeneron
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be ...
-
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to ...
-
New Board of Directors Appointments
Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development of therapeutic humanized chicken antibodies, today announced the appointments of Drs. Nadine Beauger and Louise Proulx to its Board of Directors. Dr. Beauger is currently Chief Executive Officer at IRICoR—a drug discovery-focused Centre of Excellence in Commercialization and ...
-
EnGen Bio announces a registered equity crowdfunding campaign, in partnership with WeFunder.
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health ...
-
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. (“FutureChem”) (KOSDAQ: 220100ks), a leading ...
-
CQDM to support a $1.1 million Immune Biosolutions’ research project
CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from: Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Université de Sherbrooke’s Professors ...
-
Agilent Technologies and Chungnam National University collaborate to further glycomics research
Agilent Technologies Inc. (NYSE: A) and Chungnam National University today announced an agreement to develop new applications, methods, technologies and software tools in the field of glycomics, the study of complex sugars. The university aims to identify and develop biomarkers for diseases such as cancer, leading to development of therapeutic antibody products. This announcement marks the first ...
-
Pronalyse Announces the Launch of Epitope Mapping Service Utilizing HDX-MS Technology
Pronalyse is a subdivision of Creative Proteomics, an integrated CRO company with rich experience in providing drug development services. Based on years of experience supporting protein characterization research, Creative Proteomics Pronalyse has launched the epitope mapping service utilizing HDX-MS, allowing linear and conformational epitope characterization with high resolution and the highest ...
-
Confo Therapeutics Expands Patent Estate For ConfoBody®-Based GPCR Screening Platform
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP ...
-
Bayer and Berkeley Lights announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits
Bayer announced a multi-year agreement with Berkeley Lights, Inc. (Nasdaq: BLI) a leader in the functional characterization of live biology, to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed. Berkeley Lights will leverage its platform to screen individual variants of ...
-
Engineering antibody-antigen interfaces to improve therapeutic properties
Antibodies (immunoglobulins) are a key component of the mammalian immune response and are increasingly of interest as a means of therapy for several diseases. In fact, there are over 100 monoclonal antibodies that have been approved as drugs1. Despite this apparent success, there are issues with biopharmaceutical antibody research and development – not least the cost of goods. Although it ...
-
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old ...
By Synaffix BV
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you